

An innovative and safe surgical approach for vitrectomy procedure

VITREAL[®] S

Triamcinolone Acetonide Ophthalmic Suspension

NEW

**TAKEN FROM
SCIENTIFIC
LITERATURE**



SCOFTECH italia

ofta hi-tech



NEW

An innovative and safe surgical approach
for vitrectomy procedure

VITREAL[®] S



VITREAL[®] S consists of a medical device used in endocular surgery for the colouring of the vitreous humour and removal of the epiretinal membrane under vitrectomy. The Triamcinolone micro-particles highlight the presence of the vitreous humour and the epiretinal membrane, facilitating their removal during surgery.

**TAKEN FROM
SCIENTIFIC
LITERATURE**

There are **over 700 publications¹** on the intra-vitreous use of Triamcinolone available today.



... possible RISKS of extemporary formulations

Bacterial endophthalmitis ^{2,3,4}

Due to a lack of asepsis

Sterile endophthalmitis ^{3,5,6}

- Reported in 0.87% of cases of eyes treated with Triamcinolone Acetonide for intravitreal use.⁷
- Could be due to the toxic effects of preservatives.

THE SOLUTION

■ **Triamcinolone Acetonide** suspension
in suspended saline solution at pH 7.2

■ Sterile product, ready to use

■ Does not contain preservative agents

VITREAL[®] S

ADVANTAGES


- Reduces risks related to galenic preparation
- Reduces the risks of septic contamination
- Reduces the risks of endophthalmitis
- Allows the repeated injection of the colour carrier until the vitreous mass has been completely removed (phial 2 ml)
- Enables the safe and complete removal of the vitreous, eases the surgical procedure reducing the intervention time and decreasing the occurrence of complications.

VITREAL[®] S

Triamcinolone Acetonide Ophthalmic Suspension

NEW

an innovative and safe surgical approach for vitrectomy procedure



BIBLIOGRAPHY

1 - www.pubmed.gov

2 - Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M & Sinesterra JP et al.
Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003; 136 5: 791–796.

3 - Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB & Martidis A.
Infectious and presumed non-infectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003; 23 5: 686–691.

4 - Benz MS, Murray TG, Dubovy SR, Katz RS & Eifrig CW.
Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol 2003; 121 2: 271–273.

5 - Sutter FK & Gillies MC.
Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003; 87 8: 972–974.

6 - Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL & Chaudhry NA.
Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol. 2003; 121 9: 1279–1282.

7 - Moshfeghi DM, Kaiser PK, Bakri SJ, Scott IU, Sears JE & Benz M et al.
Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging. 2005; Jan-Feb; 36 (1): 24-9.

8 - S J Bakri, A Shah, N S Falk and P M Beer.
Intravitreal preservative-free triamcinolone acetonide for the treatment of macular oedema. Eye (2005) 19, 686–688.

SOFT Italia cofla hi-tech
SOFT Italia S.p.A.
C.da Molino, 17 - 63025 Montegiorgio (FM)
www.soft.it
www.ofaht.it